Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking

OX40: Structure and function – What questions remain?

(2017) Jane Willoughby et al.   MOLECULAR IMMUNOLOGY

Targeting natural killer cells in cancer immunotherapy

(2016) Camille Guillerey et al.   NATURE IMMUNOLOGY

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice

(2016) Stefanie N. Linch et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

(2015) Theofanis Floros et al.   SEMINARS IN ONCOLOGY

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal

(2015) Stefanie N. Linch et al.   Frontiers in Oncology

Targeting CD137 enhances the efficacy of cetuximab

(2014) Holbrook E. Kohrt et al.   JOURNAL OF CLINICAL INVESTIGATION

OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

(2013) B. D. Curti et al.   CANCER RESEARCH

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

(2013) Aurélien Marabelle et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunotherapy Targeting Inhibitory Fc  Receptor IIB (CD32b) in the Mouse Is Limited by Monoclonal Antibody Consumption and Receptor Internalization

(2013) E. L. Williams et al.   JOURNAL OF IMMUNOLOGY

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

(2012) Holbrook E. Kohrt et al.   JOURNAL OF CLINICAL INVESTIGATION

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

(2011) S. H. Lim et al.   BLOOD

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Control of Immunity by the TNFR-Related Molecule OX40 (CD134)

(2010) Michael Croft   Annual Review of Immunology

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

(2010) H. E. Kohrt et al.   BLOOD

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

OX40 (CD134) expression in sentinel lymph nodes correlates with prognostic features of primary melanomas

(2008) MaryClare Sarff et al.   AMERICAN JOURNAL OF SURGERY

OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor

(2008) M. J. Gough et al.   CANCER RESEARCH

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

(2008) Silvia Piconese et al.   JOURNAL OF EXPERIMENTAL MEDICINE